IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd.

Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements.

AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF), a clinical-stage oncology company focused on advancing a new class of DNA Damage Response therapies and developing artificial intelligence-driven precision oncology solutions.

To begin the interview, Mohamed provided an overview of Onco-Innovations’ lead drug candidate, ONC010, and the company’s work targeting PNKP, a DNA repair enzyme that has not previously been targeted in a clinical-stage program.

“Onco-Innovations is a Canadian preclinical-stage precision oncology company. It’s headquartered in Calgary, and we’re developing a first-in-class DNA Damage Response inhibitor against a novel target,” Mohamed said. “That’s a DNA repair enzyme called polynucleotide kinase phosphatase, or PNKP. As far as we’re aware, there is no clinical-stage PNKP program anywhere in the world, and we hold exclusive worldwide rights to the University of Alberta’s foundational PNKP inhibitor patents together with an exclusive sublicense to the nanoparticle delivery platform that accompanies it.”

Mohamed then explained how ONC010 is designed to address a longstanding challenge with radiosensitizers and chemosensitizers by combining biological and physical mechanisms intended to selectively target cancer cells and tumor tissue.

“I would say, in one word, the big difference is selectivity,” he said. “ONC010 stacks two independent selectivity mechanisms. The first is biological selectivity. Synthetic lethality limits the drug’s lethality to cells that have already lost PTEN or SHP-1. It limits the lethality to only those cells, and healthy cells that have not lost them don’t experience this toxic effect of the drug… The second is a physical selectivity. The nanoparticle concentrates the drug within tumor tissue rather than distributing it uniformly in the body because the tumor vasculature is permeable or leaky in a way that normal vasculature isn't.”

Turning to the preclinical evidence supporting ONC010, Mohamed highlighted a University of Alberta study involving the nano-formulated PNKP inhibitor that the company intends to advance into human testing.

“In that experiment, the encapsulated drug demonstrated single-agent antitumor activity, it was tolerated at the doses tested, and it prolonged survival relative to controls,” Mohamed said. “This is a really critical outcome, and it was one of the reasons why I wanted to proceed with supporting this further as a drug candidate. The drug worked on its own. The treated animals lived longer than the controls did, and the drug was tolerable at the maximum feasible dose… That one experiment validates the whole drug development thesis all at once.”

Join IBN’s Carmel Fisher for a conversation with Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations, as he further explores ONC010’s mechanism of action and preclinical development, the company’s planned first-in-human clinical program, the potential market opportunity for DNA Damage Response therapies, its precision oncology analytics business and key milestones on the path toward clinical execution.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.Ai/Timeline

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company holds an exclusive worldwide licence to patented technology directed to the therapeutic inhibition of PNKP, a novel clinical target in DNA damage response.

For more information, visit the company’s website at www.OncoInnovations.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.IBN.Ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN
Austin, Texas
IBN.Ai
512.354.7000 Office
Editor@IBN.Ai